Preparation method of perazopanib hydrochloride impurity
This invention provides a simplified process for preparing pazopanib hydrochloride impurity C under alkaline conditions, solving the impurity control problem in existing technologies and achieving the preparation of high-purity impurity C, which has promising prospects for industrial application.
Patent Information
- Application Number
- CN202410949810.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
AI Technical Summary
Existing technologies are insufficient to effectively control impurity C in pazopanib hydrochloride, which affects drug quality and medication safety.
Through a simple process, compound 1 and compound 2 are substituted under alkaline conditions to generate impurity A, which then reacts with a nitrogen methylating agent to generate impurity B. Finally, compound 5 is substituted to generate high-purity impurity C, which is then purified using a specific molar ratio and solvent system.
The preparation of high-purity impurity C has been achieved, meeting the requirements for reference standards and showing good prospects for industrial application.
Smart Images

Figure CN118908941A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemical synthesis, and particularly relates to a method for preparing pazopanib hydrochloride impurities. Background Art
[0002] Pazopanib hydrochloride, chemical name 5-[[4-[2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide monosalt hydrochloride, is a novel oral angiogenesis inhibitor developed by GlaxoSmithKline in the United States that can interfere with the formation of new blood vessels required for the growth of stubborn tumors. Pazopanib hydrochloride was first approved for marketing in the United States on November 5, 2019 in the form of tablets under the trade name Votrinet, mainly for the treatment of renal cell carcinoma (RCC). Pazopanib was first launched in my country on February 21, 2017 by Novartis.
[0003] One of the main factors in judging the quality of drugs is the impurities contained in the drugs. The quality of drugs and the safety of patients' use of drugs mainly depend on the precise control of drug impurities. The commercial synthesis process route of pazopanib hydrochloride is detailed in the document A. Porrol, M. Zhong, Jeffrey Alan Stadford. Chemical Methods [P]. CN1688553, 2005-10-26. as shown in the figure below:
[0004]
[0005] According to the reaction mechanism, in the first step of the above synthesis route, compound 1 and compound 2 will undergo a substitution reaction to generate compound 3 and will also generate an isotopic substituted product A. The impurity A will continue to conduct and then become impurity C, which will be transferred to the API, thereby affecting the quality of the raw material.
[0006] Based on this, the synthesis of pazopanib hydrochloride impurity C is of great significance, as it can be used for qualitative research and quantitative control of impurities in the production process of pazopanib hydrochloride raw materials, thereby ensuring the safety of pazopanib hydrochloride. Summary of the invention
[0007] The object of the present invention is to provide a method for preparing a pazopanib hydrochloride impurity C, which can prepare high-purity pazopanib hydrochloride impurity C through a simple process, can meet the needs of a reference substance, and has good industrial application prospects.
[0008] The object of the present invention is achieved in the following ways:
[0009] A method for preparing pazopanib hydrochloride impurities comprises the following reaction steps:
[0010] Step 1. Compound 1 and compound 2 undergo substitution reaction under alkaline conditions to generate impurity A;
[0011] Step 2. Impurity A reacts with a nitrogen methylating agent under alkaline conditions to generate impurity B;
[0012] Step 3. Impurity B undergoes substitution reaction with compound 5 to generate impurity C;
[0013]
[0014] The specific preparation process includes:
[0015] Step 1, mixing compound 1 and compound 2 under alkaline conditions, the solvent is anhydrous ethanol, and a substitution reaction occurs at 70°C to 80°C under nitrogen protection, and the mother liquor obtained by crystallization is concentrated under reduced pressure to precipitate a solid, and the solid is separated by column chromatography, and the relevant components are collected to obtain a white solid, which is dried to obtain impurity A.
[0016] Step 2, adding a nitrogen methylation reagent to impurity A under alkaline conditions, the solvent is N,N-dimethylformamide, and a nitrogen methylation reaction occurs at room temperature under nitrogen protection, and a light yellow solid, i.e., impurity B, is obtained after crystallization, pulping purification, and drying.
[0017] Step 3, impurity B and compound 5 are mixed, the solvent is isopropanol, and the mixture is kept warm and refluxed under nitrogen protection to undergo a substitution reaction. After crystallization, pulping, purification, and drying, a light yellow solid, namely impurity C, is obtained.
[0018] The alkaline substance used in the alkaline conditions of step 1 of the present invention is one or more of triethylamine, potassium bicarbonate, and sodium bicarbonate, preferably sodium bicarbonate, and the molar ratio of compound 1 to the alkaline substance is preferably 1:2.2-2.3, and more preferably 1:2.27-2.28. Too high or too low a molar ratio will affect the reaction process.
[0019] The molar ratio of compound 1 to compound 2 in step 1 is 1:1.09-1.3, preferably 1:1.19-1.21. A molar ratio that is too low will affect the reaction process, while a molar ratio that is too high will result in low purity of the main peak.
[0020] The alkaline conditions in step 2 are one or more of sodium carbonate, potassium carbonate, and cesium carbonate. Preferably, the alkaline conditions are cesium carbonate, and the molar ratio of impurity A to cesium carbonate is 1:1.5 to 2.5. More preferably, the molar ratio of impurity A to cesium carbonate is 1:2. Too high or too low a molar ratio will affect the reaction process.
[0021] The nitrogen methylation reagent in step 2 includes one or more of methyl iodide (MeI), methyl bromide and methyl tert-butyl ether, and the molar ratio of impurity A to MeI is 1:1.1 to 1.5, preferably the molar ratio of impurity A to MeI is 1:1.1 to 1:1.15, and most preferably the molar ratio of impurity A to MeI is 1:1.1.
[0022] The purification and beating system described in step 2 is as follows: the solid obtained by crystallization is beated with a mixed solution of anhydrous ethanol and purified water, and the mass ratio of impurity A: anhydrous ethanol: purified water is 1:0.8:1.
[0023] The molar ratio of impurity B and compound 5 in step 3 is 1:1.1-1.3, preferably 1:1.1-1.2. Too low a molar ratio will affect the reaction process, while too high a molar ratio will not only lead to waste but also require additional post-processing steps to remove compound 5.
[0024] The temperature of the heat preservation reflux reaction in step 3 is 75°C to 85°C.
[0025] The two slurrying systems for purification in step 3 are as follows: first, the precipitated solid is slurried using a mixed solution of dichloromethane and methanol, and the ratio of the mass of impurity B (g) to the volume (ml) of dichloromethane and methanol is 1:10:10; then, a mixed solution of methanol and triethylamine is added to the solid for slurrying, and the ratio of the mass of impurity B (g) to the volume (ml) of methanol (ml) and triethylamine is 1:10:1.
[0026] Pazopanib hydrochloride impurity C is a conductive impurity, which is consistent with the starting material for synthesizing pazopanib hydrochloride. To obtain impurity C with high purity and to maintain a high yield, specific reaction conditions need to be screened. The present invention adopts specific preparation conditions, and further reacts and refines the impurity pazopanib hydrochloride impurity A in the process of preparing pazopanib hydrochloride, thereby obtaining pazopanib hydrochloride impurity C with high purity.
[0027] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0028] The invention provides a method for preparing the pazopanib hydrochloride impurity C, which has the advantages of simple preparation process, easy availability of raw materials and reagents, high product purity, etc., can meet the requirements of reference substances, and has good industrial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 is a high performance liquid chromatogram of pazopanib hydrochloride impurity C in Example 1;
[0030] Figure 2 is a high performance liquid chromatogram of the impurity C of pazopanib hydrochloride in Comparative Example 1;
[0031] Figure 3 It is the high performance liquid chromatogram of impurity C of pazopanib hydrochloride in Comparative Example 2. DETAILED DESCRIPTION
[0032] The present invention is further explained below by specific examples:
[0033] Example 1
[0034] Source of starting materials: 2,3-dimethyl-6-amino-2H-indazole (Compound 1), 2,4-dichloropyrimidine (Compound 2), and 3-amino-6-methylbenzenesulfonamide (Compound 5) are all produced by Shanghai Weisi Chemical Technology Co., Ltd. Impurity A: N-(4-chloropyrimidin-2-yl)-2,3-dimethyl-2H-indazol-6-amine; Impurity B: N-(4-chloropyrimidin-2-yl)-N-methyl-2,3-dimethyl-2H-indazol-6-amine; Impurity C: 5-((2-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-4-yl)amino)-2-methylbenzenesulfonamide.
[0035] (1) Under nitrogen protection, add 146g of anhydrous ethanol to the reaction bottle, start stirring, add 18g of compound 1 (0.11mol, 1.0eq) and 19.8g of compound 2 (0.133mol, 1.19eq), stir for 15min, add 20.7g of sodium bicarbonate (0.25mol, 2.2eq), heat to 70℃~80℃ for reaction, and monitor by TLC until the reaction is complete. Under nitrogen protection, control the temperature at 50℃~65℃, add 81g of purified water dropwise, keep warm and stir for 0.5h, cool the reaction bottle to 10℃~15℃, control the temperature at 10℃~15℃ and stir for crystallization for 2h. Filter and concentrate to obtain 33.4g of white solid. Use column chromatography for separation. Concentrate the collected eluate to dryness to obtain 20.24g of solid, and after drying, obtain 18.86g of white solid, i.e. impurity A, with a yield of 62.7%.
[0036] (2) Add 18.86g impurity A (0.069mol, 1.0eq), 44.89g cesium carbonate (0.138mol, 2.0eq) and 188.6mL DMF to the reaction bottle, start stirring and nitrogen protection, add 10.75g MeI (0.076mol, 1.1eq) at room temperature, stir to react, and monitor by TLC until the reaction is complete. Cool the reaction bottle to below 80°C, add 37.72g purified water dropwise, control the temperature at 55°C to 65°C and stir for 1h, separate the liquid, collect the organic phase, control the temperature at 55°C to 65°C and add 188.6g purified water dropwise to the organic phase, control the temperature at 50°C to 65°C and stir for 1h, cool to 5°C to 10°C, stir and crystallize for 5h, add 15.1g anhydrous ethanol and 18.86g purified water to the solid obtained by crystallization, and beat for 30min. Centrifuge, and slurry the solid with 75.44g purified water twice, and rinse the filter cake with 9.43g purified water after each centrifugation. The obtained solid is vacuum dried to constant weight. 18.3g of light yellow solid, namely impurity B, is obtained. The yield of this step is 92.8%.
[0037] (3) Under nitrogen protection, 18.3 g of impurity B (0.064 mol, 1.0 eq), 14.22 g of compound 5 (0.076 mol, 1.2 eq) and 183 mL of isopropanol were added to the reaction bottle, and the temperature was raised to 75°C to 85°C for reflux reaction. TLC was monitored until the reaction was completed (the reaction reached the end point after 6 hours). The reaction solution was cooled to 10°C to 15°C, stirred and crystallized for 3 hours, and centrifuged until there were no droplets. To the solid obtained by centrifugation, 183 mL of dichloromethane and 183 mL of methanol were added, the mixture was stirred at room temperature for 2 h, filtered, and vacuum dried to constant weight to obtain 24.45 g of solid. To the solid, 183 mL of methanol and 18.3 mL of triethylamine were added, the mixture was stirred at room temperature for 2 h, filtered, and the filter cake was rinsed with 30 g of dichloromethane to obtain 23.1 g of light yellow solid. The mixture was vacuum dried to constant weight to obtain 25.92 g of light yellow solid, i.e., impurity C. The yield of this step was 85.5%, and the total yield was 49.7%.
[0038] 1 H-NMR, δ: 2.46 (s, 3H); 2.63 (s, 3H); 3.51 (s, 3H); 6.12~6.13 (d, J=5.0HZ, 1H ); 6.77~6.79 (d, J=10.0HZ, 1H); 6.92~6.94 (dd, J1=0.5HZ, J2=9.5HZ, 1H); 7 .29 (s, 2H); 7.37 (s, 1H); 7.62~7.63 (d, J=5.0HZ, 1H); 7.74~7.76 (dd, J1=1. 5HZ, J2=8.5HZ, 1H); 7.93~7.94 (d, J=5.0HZ, 1H); 8.03 (s, 1H); 9.51 (s, 1H).
[0039] In the above embodiment, the chromatographic conditions for sample detection are as follows:
[0040] Chromatographic conditions and system suitability: The chromatographic column was filled with hexadecylamide bonded silica gel [Agilent ZORBAX Bonus-RP (150 mm × 4.6 mm, 3.5 μm)] or a chromatographic column of equivalent performance, with 0.1% trifluoroacetic acid aqueous solution as mobile phase A and 0.1% trifluoroacetic acid acetonitrile solution as mobile phase B. Gradient elution was performed as shown in Table 1, the detection wavelength was 268 nm, and the column temperature was 40°C.
[0041] Table 1 Elution gradient
[0042]
[0043] The HPLC chromatogram of the prepared pazopanib hydrochloride impurities is shown in Figure 1 The main peak purity of impurity C is 98.81%.
[0044] Comparative Example 1
[0045] The remaining steps are the same as in Example 1, except that in step (3), the molar ratio of impurity B to compound 5 is 1:1.6. The reaction in this step takes 9 hours to reach the end point, the yield is only 32.6%, the purity is 86.86%, and the attached Figure 2 This is the HPLC chromatogram of impurity C of pazopanib hydrochloride prepared by this process.
[0046] Comparative Example 2
[0047] The remaining steps were the same as in Example 1, except that in step (3), the purification pulping system used for 18.3 g of impurity B was only 183 mL of dichloromethane, the yield was 43.5%, the main peak purity was 81.34%, and the attached Figure 3 This is the HPLC chromatogram of impurity C of pazopanib hydrochloride prepared by this process.
Claims
1. A method for preparing pazopanib impurities, characterized in that: The method comprises the following steps: Step 1. Compound 1 and compound 2 undergo substitution reaction under alkaline conditions to generate impurity A; Step 2. Impurity A reacts with a nitrogen methylating agent under alkaline conditions to generate impurity B; Step 3. Impurity B undergoes substitution reaction with compound 5 to generate impurity C; 2. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The step 1 is specifically as follows: Compound 1 and Compound 2 are stirred and mixed under alkaline conditions, the solvent is anhydrous ethanol, a substitution reaction occurs at 70°C to 80°C under nitrogen protection, the mother liquor obtained by crystallization is concentrated under reduced pressure, a solid is precipitated, column chromatography is performed for separation, and relevant components are collected to obtain a white solid, which is dried to obtain impurity A.
3. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The step 2 is specifically as follows: adding a nitrogen methylation reagent to impurity A under alkaline conditions, the solvent is N,N-dimethylformamide, and a nitrogen methylation reaction occurs at room temperature under nitrogen protection, and a light yellow solid is obtained after crystallization, pulping purification, and drying, namely impurity B.
4. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The step 3 is specifically as follows: impurity B and compound 5 are mixed, the solvent is isopropanol, and the mixture is kept warm and refluxed under nitrogen protection to undergo a substitution reaction, and a light yellow solid, namely impurity C, is obtained after crystallization, pulping, purification, and drying.
5. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The alkaline substance used in the alkaline conditions of step 1 is one or more of triethylamine, potassium bicarbonate, and sodium bicarbonate, preferably sodium bicarbonate; the molar ratio of compound 1 to the alkaline substance is 1:2.2-2.3, preferably 1:2.27-2.
28.
6. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The molar ratio of compound 1 to compound 2 in step 1 is 1:1.09-1.3, preferably 1:1.19-1.
21.
7. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The alkaline substance used in the alkaline condition in step 2 is one or more of sodium carbonate, potassium carbonate, and cesium carbonate. Preferably, the alkaline condition is cesium carbonate, and the molar ratio of impurity A to cesium carbonate is 1:1.5-2.
5.
8. The method for preparing pazopanib hydrochloride impurities according to claim 3, characterized in that: The nitrogen methylation reagent in step 2 includes one or more of methyl iodide, methyl bromide and methyl tert-butyl ether, and the molar ratio of impurity A to MeI is 1:1.1-1.
5.
9. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The molar ratio of impurity B and compound 5 in step 3 is 1:1.1-1.
3.
10. The method for preparing pazopanib hydrochloride impurities according to claim 1, characterized in that: The substitution reaction in step 3 adopts a heat preservation reflux reaction temperature of 75°C to 85°C.
11. The method for preparing pazopanib hydrochloride impurities according to claim 4, characterized in that: The beating purification described in step 3 adopts two beatings, and the conditions are as follows: first use a mixed solution of dichloromethane and methanol to be slurried on the precipitated solid, and the volume ratio of the impurity B mass to dichloromethane and methanol is 1:10:10; filter, vacuum dry to constant weight to obtain a solid, and then add a mixed solution of methanol and triethylamine to the solid, and beat, and the mass of impurity B, the volume of methanol and the volume ratio of triethylamine are 1:10:1.
